Heart Test Laboratories

HSCS

Market cap $6.02M

Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function

Bunkerhill Health's FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences' SaaS-based, recurring-revenue marketplace strategy Bunkerhill Health's FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences' SaaS-based, recurring-revenue marketplace strategy

Agreement follows Cibolo Health's endorsement of MyoVista Insights for its network of 127 independent hospitals and reflects continued commercial momentum for HeartSciences' ECG management platform Agreement follows Cibolo Health's endorsement of MyoVista Insights for its network of 127 independent hospitals and reflects continued commercial momentum for HeartSciences' ECG management platform

Agreement with St. Vincent Health marks HeartSciences' transition from early adopter installations to commercial SaaS deployments following the full launch of MyoVista Insights at the American College of Cardiology Annual Scientific Session Agreement with St. Vincent Health marks HeartSciences' transition from early adopter installations to commercial SaaS deployments following the full launch of MyoVista Insights at the American College of Cardiology Annual Scientific Session

Southlake, TX, April 14, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), would like to remind its shareholders to vote ahead of its upcoming Annual Meeting of Shareholders (the “Annual Meeting”) which will be held virtually on Thursday, April 30, 2026, at 10:00 a.m. Eastern Time. All shareholders of record of HeartSciences' outstanding shares of common stock and Series C preferred stock at the close of business on March 6, 2026, are entitled to participate and vote at the Annual Meeting.

Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.   (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that its MyoVista Insights™ platform has received Epic Toolbox designation for the ECG Management System category.

Southlake, TX, March 24, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.   (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), will present at Investor Summit Group Virtual Conference, March 25, 2026 at 12:30 pm ET.

Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.   (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal third quarter ended January 31, 2026 (“FQ3 2026”) and provided a business update. Third Quarter and Recent Highlights During the third quarter and subsequent period, the Company continued advancing the commercialization of its MyoVista Insights™ healthcare IT platform and submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (“FDA”) for 510(k) premarket clearance.

Southlake, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.    (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that the University of the West of England (“UWE”) has adopted the Company's MyoVista Insights™ platform and MyoVista® wavECG™ device as its exclusive ECG technologies to establish a Reference Center for ECG Education and Technology.

Southlake, TX, Jan. 29, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.   (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that Cibolo Rural Health Networks (“Cibolo Health”) has selected MyoVista Insights™ as its endorsed ECG management platform for independent hospitals within its high-value networks. This collaboration will provide Cibolo Health's network of 123 independent hospitals across six states with access to a modern, cloud-native ECG management platform designed to improve workflow efficiency, data accessibility, and clinical decision-making.